Guggenheim Reaffirms Its Buy Rating on Eli Lilly & Company (LLY) with Price Target of $875

Core Insights - Eli Lilly & Company (NYSE: LLY) is recognized as one of the best non-tech stocks to buy, supported by hedge fund interest [1] - Guggenheim has reaffirmed its Buy rating on Eli Lilly with a price target of $875 [2] - Strong demand for tirzepatide in diabetes and obesity treatment, along with the upcoming launch of orforglipron, is expected to drive global growth [3] Financial Performance - Eli Lilly reported a gross profit margin of 82.64% and a revenue increase of 36.83% year-over-year [3] Regulatory Developments - The U.S. FDA authorized Guardant Health's Guardant360 CDx as a companion diagnostic for Eli Lilly's breast cancer medication Inluriyo, aiding in the identification of patients with advanced breast cancer and ESR1 mutations [4] Market Position - Eli Lilly's advancements in the metabolic and oncology sectors, combined with analyst confidence and regulatory approvals, reinforce its status as a leading global pharmaceutical company [5]